Total Payments
$20,307
2024 Payments
$3,299
Companies
20
Transactions
97
Medicare Patients
15,847
Medicare Billing
$10.4M
Payment Breakdown by Category
Consulting$10,040 (49.4%)
Food & Beverage$5,450 (26.8%)
Other$4,288 (21.1%)
Travel$527.87 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,040 | 3 | 49.4% |
| Food and Beverage | $5,450 | 87 | 26.8% |
| Acquisitions | $3,326 | 1 | 16.4% |
| Current or prospective ownership or investment interest | $931.02 | 1 | 4.6% |
| Travel and Lodging | $527.87 | 2 | 2.6% |
| Entertainment | $31.64 | 1 | 0.2% |
| Unspecified | $0 | 2 | 0.0% |
Payments by Type
General
$20,307
95 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $12,759 | 28 | $0 (2024) |
| US Retina LLC | $4,444 | 5 | $0 (2023) |
| Alcon Vision LLC | $1,167 | 14 | $0 (2024) |
| Alcon Laboratories Inc | $592.81 | 11 | $0 (2018) |
| Alimera Sciences, Inc. | $265.91 | 5 | $0 (2022) |
| EyePoint Pharmaceuticals US, Inc. | $158.90 | 3 | $0 (2023) |
| Coherus Biosciences Inc. | $143.64 | 2 | $0 (2023) |
| Biogen, Inc. | $133.41 | 1 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $121.27 | 6 | $0 (2022) |
| Astellas Pharma US Inc | $97.41 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,299 | 10 | Genentech USA, Inc. ($3,014) |
| 2023 | $6,500 | 11 | US Retina LLC ($3,326) |
| 2022 | $3,055 | 24 | US Retina LLC ($1,118) |
| 2021 | $155.51 | 2 | Alcon Vision LLC ($155.51) |
| 2020 | $193.89 | 5 | Alcon Vision LLC ($149.04) |
| 2019 | $586.96 | 17 | Alcon Vision LLC ($311.43) |
| 2018 | $605.16 | 12 | Alcon Laboratories Inc ($490.68) |
| 2017 | $5,911 | 16 | Genentech USA, Inc. ($5,691) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/03/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $120.53 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/02/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $32.14 | General |
| Category: EYE CARE | ||||||
| 09/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $122.20 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/11/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/16/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $116.06 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $122.26 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/27/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $97.41 | General |
| Category: Ophthalmology | ||||||
| 02/07/2024 | Alcon Vision LLC | NGENUITY (Device) | Food and Beverage | In-kind items and services | $138.06 | General |
| Category: Ophthalmology | ||||||
| 01/29/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: EYE CARE | ||||||
| 12/07/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $101.70 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/01/2023 | Coherus Biosciences Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: Ophthalmology | ||||||
| 09/28/2023 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $3,325.80 | General |
| 09/20/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $121.74 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/26/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $113.33 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/19/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $117.97 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 05/04/2023 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 03/16/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $130.69 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/15/2023 | Genentech USA, Inc. | Susvimo (Drug) | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/09/2023 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 2023 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/12/2022 | US Retina LLC | — | Food and Beverage | Cash or cash equivalent | $186.68 | General |
| 12/07/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $125.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/01/2022 | Alcon Vision LLC | NGENUITY (Device) | Food and Beverage | In-kind items and services | $138.80 | General |
| Category: Ophthalmology | ||||||
| 11/16/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $143.14 | General |
| Category: Immunology and Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 3,151 | 80,873 | $15.2M | $3.4M |
| 2022 | 16 | 3,427 | 22,348 | $13.5M | $3.0M |
| 2021 | 17 | 4,183 | 12,635 | $10.2M | $2.4M |
| 2020 | 18 | 5,086 | 10,059 | $6.0M | $1.5M |
Total Patients
15,847
Total Services
125,915
Medicare Billing
$10.4M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 152 | 71,040 | $8.3M | $2.1M | 24.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 84 | 2,306 | $2.9M | $411,288 | 14.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 78 | 598 | $1.8M | $403,737 | 22.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 331 | 1,815 | $795,863 | $186,782 | 23.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 650 | 985 | $395,566 | $91,519 | 23.1% |
| 92134 | Imaging of retina | Office | 2023 | 854 | 2,729 | $354,251 | $87,324 | 24.7% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 463 | 540 | $203,472 | $59,656 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 222 | 222 | $116,124 | $25,480 | 21.9% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 23 | 23 | $81,909 | $19,812 | 24.2% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 21 | 26 | $72,748 | $18,564 | 25.5% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 11 | 105 | $48,563 | $16,572 | 34.1% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 11 | 95 | $62,812 | $16,379 | 26.1% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 75 | 190 | $51,250 | $12,982 | 25.3% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 11 | 12 | $44,453 | $10,938 | 24.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 87 | 105 | $29,937 | $7,630 | 25.5% |
| 92250 | Photography of the retina | Office | 2023 | 67 | 70 | $8,713 | $1,991 | 22.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 11 | 12 | $1,872 | $464.93 | 24.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 161 | 2,096 | $6.3M | $1.5M | 23.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 91 | 2,978 | $3.7M | $659,670 | 17.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 81 | 9,780 | $1.1M | $291,633 | 25.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 338 | 1,859 | $799,250 | $181,501 | 22.7% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 640 | 1,022 | $410,425 | $92,609 | 22.6% |
| 92134 | Imaging of retina | Office | 2022 | 867 | 2,908 | $377,487 | $90,497 | 24.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 498 | 599 | $225,703 | $58,177 | 25.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 251 | 251 | $131,293 | $28,589 | 21.8% |
About Dr. Adam Martidis, MD
Dr. Adam Martidis, MD is a Ophthalmology healthcare provider based in Colorado Springs, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1881697910.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Martidis, MD has received a total of $20,307 in payments from pharmaceutical and medical device companies, with $3,299 received in 2024. These payments were reported across 97 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($10,040).
As a Medicare-enrolled provider, Martidis has provided services to 15,847 Medicare beneficiaries, totaling 125,915 services with total Medicare billing of $10.4M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Colorado Springs, CO
- Active Since 05/23/2005
- Last Updated 03/30/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1881697910
Products in Payments
- Non-Covered Product (Drug) $5,691
- Vabysmo (Drug) $3,481
- Susvimo (Drug) $2,520
- Constellation (Device) $1,173
- NGENUITY (Device) $586.24
- VABYSMO (Drug) $552.32
- Lucentis (Biological) $531.25
- ILUVIEN (Drug) $223.82
- YUTIQ (Drug) $158.90
- Udenyca (Biological) $117.97
- Izervay (Drug) $97.41
- OZURDEX (Drug) $86.92
- XIIDRA (Drug) $77.79
- EYLEA AFLIBERCEPT INJECTION (Biological) $70.21
- EYLEA (Biological) $51.06
- BROMSITE (Drug) $44.34
- Iluvien (Drug) $42.09
- LUMIGAN (Drug) $33.67
- California (Device) $31.64
- Cimerli (Biological) $25.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Colorado Springs
Dr. James Burden, Md, MD
Ophthalmology — Payments: $302,835
Ophthalmology $302,835
Dr. Steven Dewey, Md, MD
Ophthalmology — Payments: $275,298
Ophthalmology $275,298
James Lee, Md, MD
Ophthalmology — Payments: $31,764
Ophthalmology $31,764
Erik Anderson, M.d, M.D
Ophthalmology — Payments: $7,145
Ophthalmology $7,145
Dr. Jason Noble, Md, MD
Ophthalmology — Payments: $6,724
Ophthalmology $6,724
Dr. John Roberts, M.d, M.D
Ophthalmology — Payments: $5,484
Ophthalmology $5,484